The Blood and Marrow Transplant (BMT) Program at Northside Hospital is one of the largest and most comprehensive BMT programs in the Southeast and has among the best survival rates in the nation for bone marrow transplants. We are committed to providing clinical excellence and outstanding state-of-the-art and compassionate care for patients with leukemia and those undergoing blood marrow and stem cell transplantation.
Choosing a BMT center can be a difficult and overwhelming decision. The BMT Program at Northside Hospital is one of the most qualified and experienced transplant centers in the United States.
In 2015, Northside had among the best survival outcomes in United States for the seventh consecutive year (2009-15), per data released by the National Marrow Donor Program (NMDP) and The Center for International Blood and Marrow Transplant Research (CIBMTR), [*1] ,[*2]
Patients and their families are at the center of our BMT Program. Each individual is treated with respect, dignity and compassion. We believe that having you at the top of the treatment pyramid enables our team to deliver outstanding care and excellent patient satisfaction.
Our BMT Program includes:
Whether you receive your transplant in our state-of-the-art inpatient BMT unit or in the outpatient setting, you will receive the same outstanding care from our dedicated interdisciplinary team of nationally recognized physicians, mid-level practitioners, nurses, coordinators, clinical BMT Pharm D’s, a dedicated health psychologist, nutritionists, a dedicated social worker, physical therapists and ancillary specialists.
The Blood and Marrow Transplant Program at Northside Hospital is a collaboration between The Blood & Marrow Transplant Group of Georgia (BMTGA) and Northside Hospital. Our BMT physicians have completed hematopoietic stem cell transplant fellowship training at prestigious universities: Johns Hopkins School of Medicine; University of California at San Diego; National Institutes of Health; National Heart, Lung and Blood Institute; and the University of Minnesota. In addition to providing leadership to Northside’s BMT Program, these physicians manage the clinical care of patients in the hospital/outpatient setting and develop state-of-the-art clinical research protocols and treatment plans.
A physician is on call 24 hours a day, 7 days a week. For more information about referring a patient to the BMT Program at Northside, please call (404) 255-1930.
Northside Hospital offers state-of-the-art facilities for BMT and leukemia care.
Our dedicated BMT inpatient unit is a state-of-the-art closed, heap-filtered facility used solely for BMT and leukemia patients. This 36-bed unit has private rooms, a specialized pharmacy with the capabilities to mix complex chemotherapy regimens, a dedicated family room and an exercise room. Nursing and mid-level practitioners undergo extensive annual training and competency.
Additional facilities include:
The BMT Program at Northside Hospital is one of the largest clinical transplant programs in the United States, serving patients undergoing bone marrow/stem cell transplant therapy and providing primary leukemia treatment. We perform the following types of transplants:
Hematological disorders treated:
Northside Hospital Foundation works in conjunction with
community partners to meet transportation and lodging needs for
patients with leukemia, and those undergoing blood marrow and
stem cell transplantation.
The BMT Program at Northside Hospital meets the criteria of “an excellent transplant center” per guidelines established by the American Society for Blood and Marrow Transplantation, the Foundation for Cellular Therapy and the National Marrow Donor Program, are three BMT governing organizations that provide patients and family members with detailed information on how to identify an excellent transplant center through outstanding survival outcomes, experienced/trained staff, comprehensive quality management program and state-of-the-art facilities.
[*1] Reported outcome data from bethematch.org. This survival information includes only patients who received their first allogeneic transplant between January 1, 2011 and December 31, 2013 using unrelated or related donors, and who had reported follow-up.
[*2] Final 2015 Transplant Center Specific Survival Report, December 16, 2015